Skip to content

    Recently Viewed

      Listening...

      Home / Media Center / Press releases / Financial /
      Johnson & Johnson Reports 2015 First-Quarter Results:

      Johnson & Johnson Reports 2015 First-Quarter Results:

      Sales of $17.4 Billion decreased 4.1% Versus 2014 First Quarter;

      Share Article
      share to

      NEW BRUNSWICK, N.J., April 14, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.4 billion for the first quarter of 2015, a decrease of 4.1% as compared to the first quarter of 2014. Operational results increased 3.1% and the negative impact of currency was 7.2%. Domestic sales increased 5.9%. International sales decreased 12.4%, reflecting operational growth of 0.8% and a negative currency impact of 13.2%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 5.7%, domestic sales increased 9.1% and international sales increased 3.0%.*

      Net earnings and diluted earnings per share for the first quarter of 2015 were $4.3 billion and $1.53, respectively. First-quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a net gain of after-tax special items of approximately $0.1 billion, primarily related to net litigation gains partially offset by costs related to the DePuy ASR™ Hip program. First-quarter 2014 net earnings included after-tax intangible amortization expense of approximately $0.3 billion and a net gain of after-tax special items of approximately $0.3 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.4 billion and adjusted diluted earnings per share were $1.56, representing decreases of 5.9% and 4.3%, respectively, as compared to the same period in 2014.*

      “The company delivered strong underlying growth in the first quarter driven by new products and the strength of the core business. Of note is the continued robust growth of the Pharmaceutical business and the solid performance of our Consumer brands,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of our global teams who focus every day on delivering innovative solutions to address evolving health care needs.”

      The Company updated its adjusted earnings guidance for full-year 2015 to $6.04 - $6.19 per share reflecting further negative foreign currency movements. The Company’s guidance excludes the impact of after-tax intangible amortization expense and special items.

      Worldwide Consumer sales of $3.4 billion for the first quarter represented a decrease of 4.7% versus the prior year, consisting of an operational increase of 3.4% and a negative impact from currency of 8.1%. Domestic sales increased 3.8%; international sales decreased 9.7%, which reflected an operational increase of 3.1% and a negative currency impact of 12.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.7%, domestic sales increased 5.1% and international sales increased 4.5%.*

      Positive contributors to operational results were sales of TYLENOL® and MOTRIN® analgesics, digestive health and international upper-respiratory over-the-counter products; NEUTROGENA® and AVEENO® skin care products; LISTERINE® oral care products; international sales of feminine protection products; and domestic sales of baby care products.

      Worldwide Pharmaceutical sales of $7.7 billion for the first quarter represented an increase of 3.0% versus the prior year with operational growth of 10.2% and a negative impact from currency of 7.2%. Domestic sales increased 16.9%; international sales decreased 10.7%, which reflected an operational increase of 3.7% and a negative currency impact of 14.4%.

      The strong operational sales results were driven by new products and the strength of core products. New products include INVOKANA®/INVOKAMET® (canagliflozin), for the treatment of adults with type 2 diabetes; XARELTO® (rivaroxaban), an oral anticoagulant; IMBRUVICA® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; and international sales of OLYSIO®(simeprevir), for combination treatment of chronic hepatitis C in adult patients. New product sales growth was negatively impacted by lower sales of OLYSIO® (simeprevir) in the U.S. and lower sales of SOVRIAD® (simeprevir) in Japan due to competitive entrants.

      Additional contributors to operational sales growth were STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; CONCERTA® (methylphenidate HCI), for the treatment of attention deficit hyperactivity disorder; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; SIMPONI®/SIMPONI ARIA® (golimumab) and domestic sales of REMICADE® (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.

      During the quarter, the U.S. Food and Drug Administration (FDA) granted approval of IMBRUVICA® (ibrutinib) for the treatment of Waldenstrom’s Macroglobulinemia and for PREZCOBIX™ (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1). The European Commission approved VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma.

      In addition, the acquisition of XO1 Limited, a privately-held biopharmaceutical company developing the anti-thrombin antibody ichorcumab, was completed. In April, the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution was completed for $1.05 billion.

      Worldwide Medical Devices sales of $6.3 billion for the first quarter represented a decrease of 11.4% versus the prior year consisting of an operational decrease of 4.6% and a negative currency impact of 6.8%. Domestic sales decreased 6.1%; international sales decreased 15.6%, which reflected an operational decrease of 3.3% and a negative currency impact of 12.3%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.3%, domestic sales increased 1.1% and international sales increased 1.5%.*

      Primary contributors to operational growth were sales of Orthopaedic products; electrophysiology products in the Cardiovascular Care business; endocutters in the Surgical Care business; and sales of insulin delivery products in the Diabetes Care business. Sales results in the Vision Care business were negatively impacted by buying patterns and competitive pricing dynamics.

      During the quarter, the Company announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99 billion.

      About Johnson & Johnson

      Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

      * Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings and adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com.

      Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

      Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the Company’s website at www.investor.jnj.com.

      NOTE TO INVESTORS

      This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

      Johnson & Johnson and Subsidiaries










      Supplementary Sales Data






















      (Unaudited; Dollars in Millions)

      FIRST QUARTER








      Percent Change




      2015


      2014


      Total


      Operations


      Currency


      Sales to customers by












      segment of business
























      Consumer












      U.S.


      $ 1,359


      1,309


      3.8

      %

      3.8


      -


      International


      2,031


      2,248


      (9.7)


      3.1


      (12.8)




      3,390


      3,557


      (4.7)


      3.4


      (8.1)














      Pharmaceutical












      U.S.


      4,371


      3,740


      16.9


      16.9


      -


      International


      3,355


      3,758


      (10.7)


      3.7


      (14.4)




      7,726


      7,498


      3.0


      10.2


      (7.2)














      Medical Devices












      U.S.


      2,962


      3,155


      (6.1)


      (6.1)


      -


      International


      3,296


      3,905


      (15.6)


      (3.3)


      (12.3)




      6,258


      7,060


      (11.4)


      (4.6)


      (6.8)














      U.S.


      8,692


      8,204


      5.9


      5.9


      -


      International


      8,682


      9,911


      (12.4)


      0.8


      (13.2)


      Worldwide


      $ 17,374


      18,115


      (4.1)

      %

      3.1


      (7.2)


























      Johnson & Johnson and Subsidiaries










      Supplementary Sales Data























      (Unaudited; Dollars in Millions)

      FIRST QUARTER








      Percent Change




      2015


      2014


      Total


      Operations


      Currency


      Sales to customers by












      geographic area
























      U.S.


      $ 8,692


      8,204


      5.9

      %

      5.9


      -














      Europe


      4,040


      4,885


      (17.3)


      0.3


      (17.6)


      Western Hemisphere excluding U.S.


      1,639


      1,695


      (3.3)


      9.9


      (13.2)


      Asia-Pacific, Africa


      3,003


      3,331


      (9.8)


      (3.0)


      (6.8)


      International


      8,682


      9,911


      (12.4)


      0.8


      (13.2)














      Worldwide


      $ 17,374


      18,115


      (4.1)

      %

      3.1


      (7.2)






































      Johnson & Johnson and Subsidiaries









      Condensed Consolidated Statement of Earnings



















      (Unaudited; in Millions Except Per Share Figures)

      FIRST QUARTER














      2015


      2014


      Percent





      Percent




      Percent


      Increase



      Amount


      to Sales


      Amount


      to Sales


      (Decrease)


      Sales to customers

      $ 17,374


      100.0


      $ 18,115


      100.0


      (4.1)


      Cost of products sold

      5,282


      30.4


      5,455


      30.1


      (3.2)


      Selling, marketing and administrative expenses

      4,847


      27.9


      5,183


      28.6


      (6.5)


      Research and development expense

      1,899


      10.9


      1,831


      10.1


      3.7


      In-process research and development

      -


      -


      18


      0.1




      Interest (income) expense, net

      119


      0.7


      118


      0.7




      Other (income) expense, net

      (348)


      (2.0)


      86


      0.5




      Earnings before provision for taxes on income

      5,575


      32.1


      5,424


      29.9


      2.8


      Provision for taxes on income

      1,255


      7.2


      697


      3.8


      80.1


      Net earnings

      4,320


      24.9


      4,727


      26.1


      (8.6)













      Net earnings per share (Diluted)

      $ 1.53




      $ 1.64




      (6.7)













      Average shares outstanding (Diluted)

      2,826.0




      2,874.7

















      Effective tax rate

      22.5

      %



      12.9

      %
















      Adjusted earnings before provision for taxes and net earnings (1)











      Earnings before provision for taxes on income

      $ 5,630


      32.4


      $ 5,928


      32.7


      (5.0)


      Net earnings

      $ 4,418


      25.4


      $ 4,693


      25.9


      (5.9)


      Net earnings per share (Diluted)

      $ 1.56




      $ 1.63




      (4.3)


      Effective tax rate

      21.5

      %



      20.8

      %
















      (1)See Reconciliation of Non-GAAP Financial Measures.











































      Johnson & Johnson and Subsidiaries









      Reconciliation of Non-GAAP Financial Measures























      First Quarter


      % Incr. /



      (Dollars in Millions Except Per Share Data)


      2015


      2014


      (Decr.)














      Earnings before provision for taxes on income - as reported

      $ 5,575


      5,424


      2.8

      %













      Intangible asset amortization expense



      312


      368
















      Litigation gain, net




      (402)


      -
















      DePuy ASRTMHip program




      139


      -
















      Synthes integration costs




      32


      118
















      Ortho-Clinical Diagnostics divestiture net gain


      (26)


      -
















      In-process research and development



      -


      18
















      Earnings before provision for taxes on income - as adjusted

      $ 5,630


      5,928


      (5.0)

      %













      Net Earnings - as reported




      $ 4,320


      4,727


      (8.6)

      %













      Intangible asset amortization expense



      226


      267
















      Litigation gain, net




      (253)


      -
















      DePuy ASRTMHip program




      122


      -
















      Synthes integration costs




      25


      84
















      Ortho-Clinical Diagnostics divestiture net gain


      (22)


      -
















      In-process research and development



      -


      13
















      Tax benefit associated with Conor Medsystems


      -


      (398)
















      Net Earnings - as adjusted




      $ 4,418


      4,693


      (5.9)

      %













      Diluted Net Earnings per share - as reported


      $ 1.53


      1.64


      (6.7)

      %













      Intangible asset amortization expense



      0.08


      0.09
















      Litigation gain, net




      (0.09)


      -
















      DePuy ASRTMHip program




      0.04


      -
















      Synthes integration costs




      0.01


      0.03
















      Ortho-Clinical Diagnostics divestiture net gain


      (0.01)


      -
















      In-process research and development



      -


      0.01
















      Tax benefit associated with Conor Medsystems


      -


      (0.14)
















      Diluted Net Earnings per share - as adjusted


      $ 1.56


      1.63


      (4.3)

      %















































































      Johnson & Johnson and Subsidiaries








      Reconciliation of Non-GAAP Financial Measure
















      Operational Sales Growth Excluding Acquisitions and Divestitures


      FIRST QUARTER 2015 ACTUAL vs. 2014 ACTUAL














      Segments














      Consumer


      Pharmaceutical


      Medical Devices


      Total




      Operational % (1)












      WW As Reported:


      3.4%


      10.2%


      (4.6)%


      3.1%


      U.S.


      3.8%


      16.9%


      (6.1)%


      5.9%


      International


      3.1%


      3.7%


      (3.3)%


      0.8%












      Women’s Health










      K-Y ®


      0.7






      0.1


      U.S.


      1.3






      0.2


      International


      0.4






      0.1












      Wound Care / Other










      BENECOL ®


      0.7






      0.1


      U.S.


      0.0






      0.0


      International


      1.2






      0.3












      Diagnostics










      Ortho-Clinical Diagnostics






      5.9


      2.4


      U.S.






      7.2


      3.0


      International






      4.8


      1.9












      All Other Acquisitions and Divestitures


      (0.1)






      0.0


      U.S.


      0.0






      0.0


      International


      (0.2)






      (0.1)












      WW Ops excluding Acquisitions and Divestitures


      4.7%


      10.2%


      1.3%


      5.7%


      U.S.


      5.1%


      16.9%


      1.1%


      9.1%


      International


      4.5%


      3.7%


      1.5%


      3.0%












      (1)Operational growth excludes the effect of translational currency









      REPORTED SALES vs. PRIOR PERIOD ($MM)



      FIRST QUARTER







      % Change




      2015


      2014

      Reported

      Operational (1)

      Currency


      CONSUMER SEGMENT (2)









      BABY CARE









      US


      $ 111


      102

      8.8%

      8.8%

      -


      Intl


      400


      443

      -9.7%

      -0.9%

      -8.8%


      WW


      511


      545

      -6.2%

      1.0%

      -7.2%


      ORAL CARE









      US


      158


      160

      -1.3%

      -1.3%

      -


      Intl


      245


      251

      -2.4%

      8.8%

      -11.2%


      WW


      403


      411

      -1.9%

      5.0%

      -6.9%


      OTC









      US


      405


      366

      10.7%

      10.7%

      -


      Intl


      588


      645

      -8.8%

      9.1%

      -17.9%


      WW


      993


      1,011

      -1.8%

      9.6%

      -11.4%


      SKIN CARE









      US


      492


      457

      7.7%

      7.7%

      -


      Intl


      411


      457

      -10.1%

      1.5%

      -11.6%


      WW


      903


      914

      -1.2%

      4.6%

      -5.8%


      WOMEN’S HEALTH









      US


      6


      24

      -75.0%

      -75.0%

      -


      Intl


      281


      303

      -7.3%

      5.5%

      -12.8%


      WW


      287


      327

      -12.2%

      -0.4%

      -11.8%


      WOUND CARE / OTHER









      US


      187


      200

      -6.5%

      -6.5%

      -


      Intl


      106


      149

      -28.9%

      -19.7%

      -9.2%


      WW


      293


      349

      -16.0%

      -12.1%

      -3.9%











      TOTAL CONSUMER









      US


      1,359


      1,309

      3.8%

      3.8%

      -


      Intl


      2,031


      2,248

      -9.7%

      3.1%

      -12.8%


      WW


      $ 3,390


      3,557

      -4.7%

      3.4%

      -8.1%




















      See footnotes at end of schedule

















      REPORTED SALES vs. PRIOR PERIOD ($MM)



      FIRST QUARTER







      % Change




      2015


      2014

      Reported

      Operational (1)

      Currency


      PHARMACEUTICAL SEGMENT (2) (3)









      IMMUNOLOGY









      US


      $ 1,755


      1,547

      13.4%

      13.4%

      -


      Intl


      708


      796

      -11.1%

      3.1%

      -14.2%


      WW


      2,463


      2,343

      5.1%

      9.9%

      -4.8%


      REMICADE









      US


      1,055


      997

      5.8%

      5.8%

      -


      US Exports (4)


      181


      167

      8.4%

      8.4%

      -


      Intl


      364


      446

      -18.4%

      -6.2%

      -12.2%


      WW


      1,600


      1,610

      -0.6%

      2.8%

      -3.4%


      SIMPONI / SIMPONI ARIA









      US


      155


      104

      49.0%

      49.0%

      -


      Intl


      145


      155

      -6.5%

      9.7%

      -16.2%


      WW


      300


      259

      15.8%

      25.5%

      -9.7%


      STELARA









      US


      364


      279

      30.5%

      30.5%

      -


      Intl


      185


      177

      4.5%

      22.5%

      -18.0%


      WW


      549


      456

      20.4%

      27.4%

      -7.0%


      OTHER IMMUNOLOGY









      US


      -


      -

      -

      -

      -


      Intl


      14


      18

      -22.2%

      -13.7%

      -8.5%


      WW


      14


      18

      -22.2%

      -13.7%

      -8.5%


      INFECTIOUS DISEASES









      US


      412


      561

      -26.6%

      -26.6%

      -


      Intl


      563


      639

      -11.9%

      4.2%

      -16.1%


      WW


      975


      1,200

      -18.8%

      -10.2%

      -8.6%


      EDURANT









      US


      9


      5

      80.0%

      80.0%

      -


      Intl


      82


      76

      7.9%

      30.6%

      -22.7%


      WW


      91


      81

      12.3%

      33.6%

      -21.3%


      OLYSIO / SOVRIAD









      US


      98


      291

      -66.3%

      -66.3%

      -


      Intl


      136


      63

      *

      *

      **


      WW


      234


      354

      -33.9%

      -26.2%

      -7.7%


      PREZISTA / PREZCOBIX









      US


      234


      214

      9.3%

      9.3%

      -


      Intl


      193


      231

      -16.5%

      -1.6%

      -14.9%


      WW


      427


      445

      -4.0%

      3.7%

      -7.7%


      OTHER INFECTIOUS DISEASES









      US


      71


      51

      39.2%

      39.2%

      -


      Intl


      152


      269

      -43.5%

      -34.5%

      -9.0%


      WW


      223


      320

      -30.3%

      -22.8%

      -7.5%





















      REPORTED SALES vs. PRIOR PERIOD ($MM)



      FIRST QUARTER







      % Change




      2015


      2014

      Reported

      Operational (1)

      Currency











      NEUROSCIENCE









      US


      750


      601

      24.8%

      24.8%

      -


      Intl


      868


      1,037

      -16.3%

      -3.2%

      -13.1%


      WW


      1,618


      1,638

      -1.2%

      7.1%

      -8.3%


      CONCERTA / METHYLPHENIDATE









      US


      126


      35

      *

      *

      -


      Intl


      98


      115

      -14.8%

      -3.5%

      -11.3%


      WW


      224


      150

      49.3%

      58.0%

      -8.7%


      INVEGA









      US


      94


      86

      9.3%

      9.3%

      -


      Intl


      61


      79

      -22.8%

      -8.7%

      -14.1%


      WW


      155


      165

      -6.1%

      0.7%

      -6.8%


      INVEGA SUSTENNA / XEPLION









      US


      228


      182

      25.3%

      25.3%

      -


      Intl


      183


      191

      -4.2%

      12.5%

      -16.7%


      WW


      411


      373

      10.2%

      18.7%

      -8.5%


      RISPERDAL CONSTA









      US


      104


      106

      -1.9%

      -1.9%

      -


      Intl


      150


      204

      -26.5%

      -13.0%

      -13.5%


      WW


      254


      310

      -18.1%

      -9.2%

      -8.9%


      OTHER NEUROSCIENCE









      US


      198


      192

      3.1%

      3.1%

      -


      Intl


      376


      448

      -16.1%

      -4.5%

      -11.6%


      WW


      574


      640

      -10.3%

      -2.2%

      -8.1%


      ONCOLOGY









      US


      334


      240

      39.2%

      39.2%

      -


      Intl


      774


      782

      -1.0%

      15.7%

      -16.7%


      WW


      1,108


      1,022

      8.4%

      21.2%

      -12.8%


      IMBRUVICA









      US


      66


      6

      *

      *

      -


      Intl


      50


      4

      *

      *

      **


      WW


      116


      10

      *

      *

      **


      VELCADE









      US


      -


      -

      -

      -

      -


      Intl


      339


      408

      -16.9%

      -4.0%

      -12.9%


      WW


      339


      408

      -16.9%

      -4.0%

      -12.9%


      ZYTIGA









      US


      253


      229

      10.5%

      10.5%

      -


      Intl


      303


      283

      7.1%

      26.3%

      -19.2%


      WW


      556


      512

      8.6%

      19.2%

      -10.6%


      OTHER ONCOLOGY









      US


      15


      5

      *

      *

      -


      Intl


      82


      87

      -5.7%

      10.1%

      -15.8%


      WW


      97


      92

      5.4%

      20.3%

      -14.9%












      REPORTED SALES vs. PRIOR PERIOD ($MM)



      FIRST QUARTER







      % Change




      2015


      2014

      Reported

      Operational (1)

      Currency


      CARDIOVASCULAR / METABOLISM / OTHER (5)









      US


      1,120


      791

      41.6%

      41.6%

      -


      Intl


      442


      504

      -12.3%

      -0.8%

      -11.5%


      WW


      1,562


      1,295

      20.6%

      25.1%

      -4.5%


      XARELTO









      US


      441


      319

      38.2%

      38.2%

      -


      Intl


      -


      -

      -

      -

      -


      WW


      441


      319

      38.2%

      38.2%

      0.0%


      INVOKANA / INVOKAMET









      US


      266


      93

      *

      *

      -


      Intl


      12


      1

      *

      *

      **


      WW


      278


      94

      *

      *

      **


      PROCRIT / EPREX









      US


      163


      176

      -7.4%

      -7.4%

      -


      Intl


      106


      134

      -20.9%

      -7.5%

      -13.4%


      WW


      269


      310

      -13.2%

      -7.4%

      -5.8%


      OTHER









      US


      250


      203

      23.2%

      23.2%

      -


      Intl


      324


      369

      -12.2%

      -1.7%

      -10.5%


      WW


      574


      572

      0.3%

      7.1%

      -6.8%











      TOTAL PHARMACEUTICAL









      US


      4,371


      3,740

      16.9%

      16.9%

      -


      Intl


      3,355


      3,758

      -10.7%

      3.7%

      -14.4%


      WW


      $ 7,726


      7,498

      3.0%

      10.2%

      -7.2%




















      Supplemental Sales Information











      2014




      Q1


      Q2

      Q3

      Q4

      Full Year


      INVOKANA / INVOKAMET









      US


      93


      114

      169

      193

      569


      Intl


      1


      3

      5

      8

      17


      WW


      94


      117

      174

      201

      586


      IMBRUVICA









      US


      6


      33

      42

      64

      145


      Intl


      4


      9

      14

      28

      55


      WW


      10


      42

      56

      92

      200











      See footnotes at end of schedule










      REPORTED SALES vs. PRIOR PERIOD ($MM)



      FIRST QUARTER







      % Change




      2015


      2014

      Reported

      Operational (1)

      Currency


      MEDICAL DEVICES (2)









      CARDIOVASCULAR CARE









      US


      $ 228


      205

      11.2%

      11.2%

      -


      Intl


      301


      336

      -10.4%

      3.4%

      -13.8%


      WW


      529


      541

      -2.2%

      6.4%

      -8.6%


      DIABETES CARE









      US


      212


      192

      10.4%

      10.4%

      -


      Intl


      272


      320

      -15.0%

      0.6%

      -15.6%


      WW


      484


      512

      -5.5%

      4.2%

      -9.7%


      DIAGNOSTICS (6)









      US


      -


      224

      **

      **

      -


      Intl


      30


      219

      -86.3%

      -83.5%

      -2.8%


      WW


      30


      443

      -93.2%

      -91.8%

      -1.4%


      ORTHOPAEDICS









      US


      1,309


      1,292

      1.3%

      1.3%

      -


      Intl


      1,019


      1,129

      -9.7%

      2.9%

      -12.6%


      WW


      2,328


      2,421

      -3.8%

      2.1%

      -5.9%


      SPECIALTY SURGERY / OTHER









      US


      417


      417

      0.0%

      0.0%

      -


      Intl


      416


      457

      -9.0%

      3.5%

      -12.5%


      WW


      833


      874

      -4.7%

      1.8%

      -6.5%


      SURGICAL CARE









      US


      543


      539

      0.7%

      0.7%

      -


      Intl


      880


      969

      -9.2%

      3.0%

      -12.2%


      WW


      1,423


      1,508

      -5.6%

      2.3%

      -7.9%


      VISION CARE









      US


      253


      286

      -11.5%

      -11.5%

      -


      Intl


      378


      475

      -20.4%

      -7.5%

      -12.9%


      WW


      631


      761

      -17.1%

      -9.0%

      -8.1%











      TOTAL MEDICAL DEVICES









      US


      2,962


      3,155

      -6.1%

      -6.1%

      -


      Intl


      3,296


      3,905

      -15.6%

      -3.3%

      -12.3%


      WW


      $ 6,258


      7,060

      -11.4%

      -4.6%

      -6.8%


















      * Percentage greater than 100%







      ** Not meaningful









      (1) Operational growth excludes the effect of translational currency




      (2) Unaudited









      (3) Prior year amounts have been reclassified to conform to current year product disclosure


      (4) Reported as U.S. sales








      (5) Previously referred to as Other







      (6) Reflects Diagnostics divestiture June 30, 2014















      SOURCE Johnson & Johnson

      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.